Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.

Get access to Brad Slager's "Riffed From the Headlines," a daily VIP feature where he looks to bring accountability to the ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

In an episode of "The David Rubenstein Show: Peer to Peer Conversations," CEO Dave Ricks talks about how the company will begin studies this year to see if its weight-loss medicines can also be ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Brian Bradley and Rick Peckham remain a part of the Lightning after careers with the team that began in the 1990s. They will ...

Dolly Parton chats with Rick Bragg on her Tennessee childhood, the real Jolene, and Dollywood's 40th anniversary.

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on Tuesday, Jan. 14 at 5:15 p.m. Eastern time. A live audio webcast will be available on the "Webcasts & Presentations ...

We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...

Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs ...